Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dinitrophenyl-modified ovarian cancer vaccine
- Development stage
- Phase 2
- Lead developer
- AVAX Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**OVax** is an investigational personalized therapeutic cancer vaccine developed by AVAX Technologies for relapsed advanced ovarian cancer. It is manufactured from a patient's own surgically obtained ovarian tumor cells, which are modified with the hapten 2,4-dinitrophenol to increase immunogenicity. The intended mechanism is induction of cellular antitumor immunity, including cytotoxic T-lymphocyte responses against patient-specific ovarian tumor antigens. OVax was evaluated in a Phase 1/2 study in patients with relapsed stage III or IV ovarian carcinoma, including platinum-resistant disease. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-dinitrophenyl-modified-ovarian-cancer-vaccine))
- Brand names
- OVax
- Other names
- autologous DNP-modified ovarian cancer vaccineDNP-conjugated autologous ovarian tumor cell vaccine antigenO-Vax
Beyond the preview
Go deeper on autologous dinitrophenyl-modified ovarian cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dinitrophenyl-modified ovarian cancer vaccine.